Avadel Pharmaceuticals (AVDL) Receives News Impact Rating of 0.07

Media stories about Avadel Pharmaceuticals (NASDAQ:AVDL) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.8026871810961 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

AVDL has been the subject of a number of analyst reports. BidaskClub upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 2nd. Ladenburg Thalmann decreased their price target on Avadel Pharmaceuticals to $24.00 and set a “buy” rating for the company in a research note on Friday, March 9th. ValuEngine upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Zacks Investment Research upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $20.00.

AVDL stock opened at $7.38 on Friday. The company has a market capitalization of $295.82, a price-to-earnings ratio of 23.81 and a beta of 1.55. Avadel Pharmaceuticals has a twelve month low of $6.71 and a twelve month high of $11.93.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings results on Thursday, March 8th. The company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). The company had revenue of $34.20 million during the quarter, compared to the consensus estimate of $34.16 million. Avadel Pharmaceuticals had a net margin of 38.64% and a return on equity of 15.40%. The business’s revenue for the quarter was down 20.6% compared to the same quarter last year. equities research analysts predict that Avadel Pharmaceuticals will post -1.29 EPS for the current year.

Avadel Pharmaceuticals announced that its board has initiated a share buyback plan on Tuesday, March 27th that allows the company to repurchase $7.00 million in shares. This repurchase authorization allows the company to repurchase up to 2.7% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/avadel-pharmaceuticals-avdl-receives-news-impact-rating-of-0-07.html.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply